Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL: ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013, 34: 3035-3087.
Article
PubMed
Google Scholar
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002, 324: 71-86.
Crescente M, Di Castelnuovo A, Iacoviello L, Vermylen J, Cerletti C, de Gaetano G: Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost. 2008, 99: 14-26.
CAS
PubMed
Google Scholar
Simpson SH, Abdelmoneim AS, Omran D, Featherstone TR: Prevalence of high on-treatment platelet reactivity in diabetic patients treated with aspirin. Am J Med. 2014, 127: 95-e1-9
Article
PubMed
Google Scholar
Takahashi S, Ushida M, Komine R, Shimizu A, Uchida T, Ishihara H, Shibano T, Watanabe G, Ikeda Y, Murata M: Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thromb Res. 2007, 119: 517-524.
Article
CAS
PubMed
Google Scholar
Ertugrul DT, Tutal E, Yildiz M, Akin O, Yalçin AA, Ure OS, Yilmaz H, Yavuz B, Deveci OS, Ata N, Küçükazman M: Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010, 95: 2897-2901.
Article
CAS
PubMed
Google Scholar
Mylotte D, Kavanagh GF, Peace AJ, Tedesco AF, Carmody D, O'Reilly M, Foley DP, Thompson CJ, Agha A, Smith D, Kenny D: Platelet reactivity in type 2 diabetes mellitus: a comparative analysis with survivors of myocardial infarction and the role of glycaemic control. Platelets. 2012, 23: 439-446.
Article
CAS
PubMed
Google Scholar
DiChiara J, Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA, Bailon O, Singla A, Gurbel PA: The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes. 2007, 56: 3014-3019.
Article
CAS
PubMed
Google Scholar
Mortensen SB, Larsen SB, Grove EL, Kristensen SD, Hvas AM: Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Thromb Res. 2010, 126: e318-e322.
Article
CAS
PubMed
Google Scholar
Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, Golanski J, Sitkiewicz D, Pregowski J, Gorski J, Zembala M, Opolski G, Huber K, Arnesen H, Kristensen SD, De Caterina R: Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2009, 30: 426-435.
Article
PubMed
Google Scholar
Viswanathan GN, Marshall SM, Balasubramaniam K, Badimon JJ, Zaman AG: Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome. Thromb Res. 2014, 133: 880-885.
Article
PubMed Central
CAS
PubMed
Google Scholar
Grove EL, Gregersen S: Antiplatelet therapy in patients with diabetes mellitus. Curr Vasc Pharmacol. 2012, 10: 494-505.
Article
CAS
PubMed
Google Scholar
Würtz M, Grove EL: Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance. Curr Pharm Des. 2012, 18: 5344-5361.
Article
PubMed
Google Scholar
Watala C, Pluta J, Golanski J, Rozalski M, Czyz M, Trojanowski Z, Drzewoski J: Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med (Berl). 2005, 83: 148-158.
Article
CAS
Google Scholar
Schneider DJ: Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care. 2009, 32: 525-527.
Article
PubMed Central
CAS
PubMed
Google Scholar
Assert R, Scherk G, Bumbure A, Pirags V, Schatz H, Pfeiffer AF: Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia. 2001, 44: 188-195.
Article
CAS
PubMed
Google Scholar
Russo I, Viretto M, Barale C, Mattiello L, Doronzo G, Pagliarino A, Cavalot F, Trovati M, Anfossi G: High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets. Diabetes. 2012, 61: 2913-2921.
Article
PubMed Central
CAS
PubMed
Google Scholar
Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B, Kropiwnicka A, Drzewoski J: Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res. 2004, 113: 101-113.
Article
CAS
PubMed
Google Scholar
Lemkes BA, Bähler L, Kamphuisen PW, Stroobants AK, Van Den Dool EJ, Hoekstra JB, Nieuwland R, Gerdes VE, Holleman F: The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus. J Thromb Haemost. 2012, 10: 639-646.
Article
CAS
PubMed
Google Scholar
Hovens MM, Snoep JD, Groeneveld Y, Tamsma JT, Eikenboom JC, Huisman MV: High levels of low-density lipoprotein cholesterol and triglycerides and suboptimal glycemic control predict diminished ex vivo aspirin responsiveness in patients with Type 2 diabetes. J Thromb Haemost. 2007, 5: 1562-1564.
Article
CAS
PubMed
Google Scholar
Cohen HW, Crandall JP, Hailpern SM, Billett HH: Aspirin resistance associated with HbA1c and obesity in diabetic patients. J Diabetes Complications. 2008, 22: 224-228.
Article
PubMed
Google Scholar
Pulcinelli FM, Biasucci LM, Riondino S, Giubilato S, Leo A, Di Renzo L, Trifirò E, Mattiello T, Pitocco D, Liuzzo G, Ghirlanda G, Crea F: COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur Heart J. 2009, 30: 1279-1286.
Article
CAS
PubMed
Google Scholar
Le Guyader A, Pacheco G, Seaver N, Davis-Gorman G, Copeland J, McDonagh PF: Inhibition of platelet GPIIb-IIIa and P-selectin expression by aspirin is impaired by stress hyperglycemia. J Diabetes Complications. 2009, 23: 65-70.
Article
PubMed
Google Scholar
Tasdemir E, Toptas T, Demir C, Esen R, Atmaca M: Aspirin resistance in patients with type II diabetes mellitus. Ups J Med Sci. 2014, 119: 25-31.
Article
PubMed Central
PubMed
Google Scholar
Hankey GJ, Eikelboom JW: Aspirin resistance. Lancet. 2006, 367: 606-617.
Article
CAS
PubMed
Google Scholar
Basili S, Pacini G, Guagnano MT, Manigrasso MR, Santilli F, Pettinella C, Ciabattoni G, Patrono C, Davì G: Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol. 2006, 48: 2531-2538.
Article
CAS
PubMed
Google Scholar
Yassine HN, Davis-Gorman G, Stump CS, Thomson SS, Peterson J, McDonagh PF: Clinical determinants of aspirin resistance in diabetes. Diabetes Res Clin Pract. 2010, 90: e19-e21.
Article
PubMed Central
PubMed
Google Scholar
Graziani F, Biasucci LM, Cialdella P, Liuzzo G, Giubilato S, Della Bona R, Pulcinelli FM, Iaconelli A, Mingrone G, Crea F: Thromboxane production in morbidly obese subjects. Am J Cardiol. 2011, 107: 1656-1661.
Article
CAS
PubMed
Google Scholar
Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Goldfine AB: Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol. 2006, 97: 567-570.
Article
CAS
PubMed
Google Scholar
Postula M, Kaplon-Cieslicka A, Rosiak M, Kondracka A, Serafin A, Filipiak KJ, Czlonkowski A, Opolski G, Janicki PK: Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: evaluation of 27 polymorphisms within candidate genes. J Thromb Haemost. 2011, 9: 2291-2301.
Article
CAS
PubMed
Google Scholar
Kapłon-Cieślicka A, Rosiak M, Postuła M, Serafin A, Kondracka A, Opolski G, Filipiak KJ: Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes. Kardiol Pol. 2013, 71: 893-902.
Article
PubMed
Google Scholar
Rosiak M, Postuła M, Kapłon-Cieślicka A, Trzepla E, Filipiak KJ, Członkowski A, Opolski G: The effect of doubling the dose of acetylsalicylic acid (ASA) on platelet function parameters in patients with type 2 diabetes and platelet hyperreactivity during treatment with 75 mg of ASA: a subanalysis of the AVOCADO study. Kardiol Pol. 2013, 71: 552-557.
Article
PubMed
Google Scholar
Meen O, Brosstad F, Khiabani H, Gjertsen E, Lauritsen ME, Pedersen TM, Bjørnsen S, Schjelderup NM, Ameln W, Ng EC, Wettergreen M, Siddique SP, Erikssen G: No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography. Scand J Clin Lab Invest. 2008, 68: 185-1891.
Article
CAS
PubMed
Google Scholar
Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, Fitzgerald DJ: Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol. 2005, 46: 1258-1263.
Article
CAS
PubMed
Google Scholar
Frelinger AL, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD: Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation. 2009, 120: 2586-2596.
Article
CAS
PubMed
Google Scholar
Standards of medical care in diabetes - 2014. Diabetes Care. 2014, 37: S14-S80.
Dolasık I, Sener SY, Celebı K, Aydın ZM, Korkmaz U, Canturk Z: The effect of metformin on mean platelet volume in dıabetıc patients. Platelets. 2013, 24: 118-121.
Article
PubMed
Google Scholar
Ferguson AD, Dokainish H, Lakkis N: Aspirin and clopidogrel response variability: review of the published literature. Tex Heart Inst J. 2008, 35: 313-320.
PubMed Central
PubMed
Google Scholar
Hubbard RE, O'Mahony MS, Calver BL, Woodhouse KW: Plasma esterases and inflammation in ageing and frailty. Eur J Clin Pharmacol. 2008, 64: 895-900.
Article
CAS
PubMed
Google Scholar
Singh S, Nain CK, Verma M, Leelamma CO, Goel RC: Aspirin esterases in North-West Indians: the influence of age and nutrition. Int J Clin Pharmacol Ther. 2000, 38: 315-319.
Article
CAS
PubMed
Google Scholar
Summerbell J, Yelland C, Woodhouse K: The kinetics of plasma aspirin esterase in relation to old age and frailty. Age Ageing. 1990, 19: 128-130.
Article
CAS
PubMed
Google Scholar
Gresner P, Dolník M, Waczulíková I, Bryszewska M, Sikurová L, Watala C: Increased blood plasma hydrolysis of acetylsalicylic acid in type 2 diabetic patients: a role of plasma esterases. Biochim Biophys Acta. 2006, 1760: 207-215.
Article
CAS
PubMed
Google Scholar
Christensen KH, Grove EL, Würtz M, Kristensen SD, Hvas AM: Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes. Platelets. 2014, ᅟ: ᅟ-in press
Google Scholar
Henry P, Vermillet A, Boval B, Guyetand C, Petroni T, Dillinger JG, Sideris G, Sollier CB, Drouet L: 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost. 2011, 105: 336-344.
Article
CAS
PubMed
Google Scholar
Rocca B, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E, Lattanzio S, Mattoscio D, Zaccardi F, Liani R, Vazzana N, Del Ponte A, Ferrante E, Martini F, Cardillo C, Morosetti R, Mirabella M, Ghirlanda G, Davì G, Patrono C: The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost. 2012, 10: 1220-1230.
Article
CAS
PubMed
Google Scholar
Dillinger JG, Drissa A, Sideris G, Bal dit Sollier C, Voicu S, Manzo Silberman S, Logeart D, Drouet L, Henry P: Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. Am Heart J. 2012, 164: 600-606.
Article
CAS
PubMed
Google Scholar
Spectre G, Arnetz L, Östenson CG, Brismar K, Li N, Hjemdahl P: Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thromb Haemost. 2011, 106: 491-499.
Article
PubMed
Google Scholar
Addad F, Chakroun T, Elalamy I, Abderazek F, Chouchene S, Dridi Z, Gerotziafas GT, Hatmi M, Hassine M, Gamra H: Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. Int J Hematol. 2010, 92: 296-301.
Article
CAS
PubMed
Google Scholar
Capodanno D, Patel A, Dharmashankar K, Ferreiro JL, Ueno M, Kodali M, Tomasello SD, Capranzano P, Seecheran N, Darlington A, Tello-Montoliu A, Desai B, Bass TA, Angiolillo DJ: Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv. 2011, 4: 180-187.
Article
CAS
PubMed
Google Scholar
Monteiro PF, Morganti RP, Delbin MA, Calixto MC, Lopes-Pires ME, Marcondes S, Zanesco A, Antunes E: Platelet hyperaggregability in high-fat fed rats: a role for intraplatelet reactive-oxygen species production. Cardiovasc Diabetol. 2012, 11: 5-
Article
PubMed Central
CAS
PubMed
Google Scholar
Kim JD, Park CY, Ahn KJ, Cho JH, Choi KM, Kang JG, Kim JH, Lee KY, Lee BW, Mok JO, Moon MK, Park JY, Park SW: Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes. Atherosclerosis. 2014, 234: 146-151.
Article
CAS
PubMed
Google Scholar
Larsen SB, Grove EL, Kristensen SD, Hvas AM: Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease. Thromb Haemost. 2013, 109: 920-999.
Article
CAS
PubMed
Google Scholar
Davì G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C: Platelet activation in obese women: role of inflammation and oxidant stress. JAMA. 2002, 288: 2008-2014.
Article
PubMed
Google Scholar
Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA: Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation. 2013, 127: 377-385.
Article
PubMed Central
CAS
PubMed
Google Scholar
Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ: Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke. 2006, 37: 2153-2158.
Article
CAS
PubMed
Google Scholar
Peace A, McCall M, Tedesco T, Kenny D, Conroy RM, Foley D, Cox D: The role of weight and enteric coating on aspirin response in cardiovascular patients. J Thromb Haemost. 2010, 8: 2323-2325.
Article
CAS
PubMed
Google Scholar
Lee S, Kwak HB: Role of adiponectin in metabolic and cardiovascular disease. J Exerc Rehabil. 2014, 10: 54-59.
Article
PubMed Central
PubMed
Google Scholar
Sulistyoningrum DC, Gasevic D, Lear SA, Ho J, Mente A, Devlin AM: Total and high molecular weight adiponectin and ethnic-specific differences in adiposity and insulin resistance: a cross-sectional study. Cardiovasc Diabetol. 2013, 12: 170-
Article
PubMed Central
PubMed
Google Scholar
Rabe K, Lehrke M, Parhofer KG, Broedl UC: Adipokines and insulin resistance. Mol Med. 2008, 14: 741-751.
Article
PubMed Central
CAS
PubMed
Google Scholar
Fisman EZ, Tenenbaum A: Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?. Cardiovasc Diabetol. 2014, 13: 103-
Article
PubMed Central
PubMed
Google Scholar
Mather KJ, Funahashi T, Matsuzawa Y, Edelstein S, Bray GA, Kahn SE, Crandall J, Marcovina S, Goldstein B, Goldberg R: Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes. 2008, 57: 980-986.
Article
PubMed Central
CAS
PubMed
Google Scholar
Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, Yamaguchi M, Tanabe H, Kimura-Someya T, Shirouzu M, Ogata H, Tokuyama K, Ueki K, Nagano T, Tanaka A, Yokoyama S, Kadowaki T: A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature. 2013, 503: 493-499.
Article
CAS
PubMed
Google Scholar
Kato H, Kashiwagi H, Shiraga M, Tadokoro S, Kamae T, Ujiie H, Honda S, Miyata S, Ijiri Y, Yamamoto J, Maeda N, Funahashi T, Kurata Y, Shimomura I, Tomiyama Y, Kanakura Y: Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol. 2006, 26: 224-230.
Article
CAS
PubMed
Google Scholar
Restituto P, Colina I, Varo JJ, Varo N: Adiponectin diminishes platelet aggregation and sCD40L release. Potential role in the metabolic syndrome. Am J Physiol Endocrinol Metab. 2010, 298: E1072-E1077.
Article
CAS
PubMed
Google Scholar
Hara K, Omori K, Sumioka Y, Aso Y: Spontaneous platelet aggregation evaluated by laser light scatter in patients with type 2 diabetes: effects of short-term improved glycemic control and adiponectin. Transl Res. 2012, 159: 15-24.
Article
CAS
PubMed
Google Scholar
Elbatarny HS, Netherton SJ, Ovens JD, Ferguson AV, Maurice DH: Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: implication in obesity-associated cardiovascular diseases. Eur J Pharmacol. 2007, 558: 7-13.
Article
CAS
PubMed
Google Scholar
Wang WQ, Zhang HF, Gao GX, Bai QX, Li R, Wang XM: Adiponectin inhibits hyperlipidemia-induced platelet aggregation via attenuating oxidative/nitrative stress. Physiol Res. 2011, 60: 347-354.
CAS
PubMed
Google Scholar
Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ: Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003, 278: 45021-45026.
Article
CAS
PubMed
Google Scholar
Addabbo F, Nacci C, De Benedictis L, Leo V, Tarquinio M, Quon MJ, Montagnani M: Globular adiponectin counteracts VCAM-1-mediated monocyte adhesion via AdipoR1/NF-κB/COX-2 signaling in human aortic endothelial cells. Am J Physiol Endocrinol Metab. 2011, 301: E1143-E1154.
Article
CAS
PubMed
Google Scholar
Shoji T, Koyama H, Fukumoto S, Maeno T, Yokoyama H, Shinohara K, Emoto M, Shoji T, Yamane T, Hino M, Shioi A, Nishizawa Y: Platelet activation is associated with hypoadiponectinemia and carotid atherosclerosis. Atherosclerosis. 2006, 188: 190-195.
Article
CAS
PubMed
Google Scholar